Cinclus Pharma Holding Ab
Clinical trials sponsored by Cinclus Pharma Holding Ab, explained in plain language.
A pharmaceutical holding company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New GERD drug aims to heal esophagus damage when standard treatments fail
Disease control CompletedThis study tests an experimental drug called X842 in people with severe erosive esophagitis caused by GERD (chronic acid reflux). Participants have either severe esophagus damage (grades C or D) or milder damage that hasn't healed after 8 weeks of standard treatment. The trial co…
Phase: PHASE2 • Sponsor: Cinclus Pharma Holding AB • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug X842 tested in healthy people for first time
Knowledge-focused CompletedThis early-phase trial tested the safety and tolerability of a drug called X842 in 39 healthy adults. Participants received either single or multiple doses of X842 to see how the body handles it and what side effects may occur. The study is complete and does not aim to treat any …
Phase: EARLY_PHASE1 • Sponsor: Cinclus Pharma Holding AB • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
12 healthy volunteers test drug combo in Early-Stage study
Knowledge-focused CompletedThis early-stage study looked at how a new GERD drug, linaprazan glurate, changes the way the body processes the antibiotic amoxicillin. Twelve healthy adults took amoxicillin alone and then again after a week of the GERD drug. The goal was to measure drug levels in the blood, no…
Phase: PHASE1 • Sponsor: Cinclus Pharma Holding AB • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC